Third-generation anti-CD19 CAR T-cells demonstrate efficacy without neurotoxicity in B-cell lymphoma phase 1 clinical trial
- News
- Updated December 13, 2023
Adding a new CAR co-stimulatory domain…
Searched everything and got 1123 results
Philanthropic partnership sees record $15 million boost to biomedical research
- News
- Updated December 12, 2023
Research into cancer, infectious…
Scope 82 | Trial results offer hope to Kiwis with incurable blood cancer
- Scope newsletters
- Updated November 21, 2023
Annual Report 2023
- Annual reports
- Updated November 13, 2023
Freemasons New Zealand renews support for CAR T-cell therapy
- News
- Updated November 10, 2023
Freemasons New Zealand has continued…
In Focus: A gateway for toxic damage and immune health
- News
- Updated November 8, 2023
A cellular receptor, once notorious for…
RNZ: Engineering immune cells to kill cancer
- News
- Updated November 5, 2023
RNZ's Kim Hill discusses the results of…
Trial results offer hope to Kiwis with incurable blood cancer
- News
- Updated November 3, 2023
New Zealand’s first trial of a…
BioOra appoints CAR T-cell therapy pioneer, Professor Carl June to Board
- News
- Updated October 31, 2023
BioOra, the Malaghan Institute’s…
COVID proved the therapeutic potential of RNA technology – making it more available is the next goal
- News
- Updated October 27, 2023
Considered a pipe dream not too long…